IN8bio (INAB) vs Intensity Therapeutics (INTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Intensity Therapeutics (INTS) over the past year, losing 42.7% versus a loss of 48.4%. IN8bio is the larger company by market cap ($13.6 million vs $12.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | INTS |
|---|---|---|
| Share price | $1.38 | $3.68 |
| Market cap | $13.60M | $12.01M |
| 1-day change | -1.43% | -3.16% |
| YTD return | -41.03% | -64.10% |
| 1-year return | -42.74% | -48.35% |
| 5-year return | -99.23% | — |
| EPS (TTM) | $-1.62 | $-3.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $43.50 |
| 52-week low | $0.88 | $3.21 |
| Distance from 52-week high | -49.45% | -91.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +407.25% | +425.27% |
| Average volume | 58.36K | 25.93K |
| Shares outstanding | 9.86M | 3.26M |
| Employees | 18 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
INAB vs INTS FAQ
Which is bigger, IN8bio or Intensity Therapeutics?
IN8bio (INAB) is larger, with a market capitalization of $13.60M compared with $12.01M for Intensity Therapeutics (INTS).
Which stock has performed better over the past year, INAB or INTS?
INAB returned -42.74% over the past 12 months, compared with -48.35% for INTS (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Intensity Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.